WA
ENGNW icon

Whitebox Advisors’s enGene Therapeutics Warrants ENGNW Stock Holding History

Whitebox Advisors’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,000
Closed -$22K – 507
2025
Q3 		$22K Hold
31,000
– – ﹤0.01% 371
2025
Q2 		$25.4K Hold
31,000
– – ﹤0.01% 330
2025
Q1 		$18.6K Sell
31,000
-2,333
-7% -$1.92K ﹤0.01% 256
2024
Q4 		$28.1K Hold
33,333
– – ﹤0.01% 198
2024
Q3 		$70K Hold
33,333
– – ﹤0.01% 180
2024
Q2 		$39.7K Hold
33,333
– – ﹤0.01% 191
2024
Q1 		$173K Hold
33,333
– – ﹤0.01% 163
2023
Q4 		$28.3K Buy
+33,333
New +$25.6K ﹤0.01% 147

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Whitebox Advisors's ENGNW Position: Q4 2025 in Review

Whitebox Advisors sold out of enGene Therapeutics Warrants (ENGNW) in Q4 2025, closing a stake of 31,000 shares — an estimated $22K sold.

Whitebox Advisors first reported a position in ENGNW in Q4 2023 and held it in 8 quarters. The position peaked at $173K in Q1 2024. 14 funds tracked by Wall St. Rank hold ENGNW as of Q4 2025.

  • Whitebox Advisors reported no remaining enGene Therapeutics Warrants position as of Q4 2025 after selling out during the quarter.
  • Whitebox Advisors sold 31,000 enGene Therapeutics Warrants shares in Q4 2025, an estimated $22K.
  • Whitebox Advisors first reported a position in enGene Therapeutics Warrants in Q4 2023 and held it in 8 quarters.
  • Whitebox Advisors's enGene Therapeutics Warrants position peaked at $173K in Q1 2024.
  • 14 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q4 2025.

Based on Whitebox Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.